Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 47 entries
Sorted by: Best Match Show Resources per page
Trial watch: Naked and vectored DNA-based anticancer vaccines.

Oncoimmunology

Bloy N, Buqué A, Aranda F, Castoldi F, Eggermont A, Cremer I, Sautès-Fridman C, Fucikova J, Galon J, Spisek R, Tartour E, Zitvogel L, Kroemer G, Galluzzi L.
PMID: 26155408
Oncoimmunology. 2015 Apr 02;4(5):e1026531. doi: 10.1080/2162402X.2015.1026531. eCollection 2015 May.

One type of anticancer vaccine relies on the administration of DNA constructs encoding one or multiple tumor-associated antigens (TAAs). The ultimate objective of these preparations, which can be naked or vectored by non-pathogenic viruses, bacteria or yeast cells, is...

Cite
Bloy N, Buqué A, Aranda F, et al. Trial watch: Naked and vectored DNA-based anticancer vaccines. Oncoimmunology. 2015;4(5):e1026531doi: 10.1080/2162402X.2015.1026531.
Bloy, N., Buqué, A., Aranda, F., Castoldi, F., Eggermont, A., Cremer, I., Sautès-Fridman, C., Fucikova, J., Galon, J., Spisek, R., Tartour, E., Zitvogel, L., Kroemer, G., & Galluzzi, L. (2015). Trial watch: Naked and vectored DNA-based anticancer vaccines. Oncoimmunology, 4(5), e1026531. https://doi.org/10.1080/2162402X.2015.1026531
Bloy, Norma, et al. "Trial watch: Naked and vectored DNA-based anticancer vaccines." Oncoimmunology vol. 4,5 (2015): e1026531. doi: https://doi.org/10.1080/2162402X.2015.1026531
Bloy N, Buqué A, Aranda F, Castoldi F, Eggermont A, Cremer I, Sautès-Fridman C, Fucikova J, Galon J, Spisek R, Tartour E, Zitvogel L, Kroemer G, Galluzzi L. Trial watch: Naked and vectored DNA-based anticancer vaccines. Oncoimmunology. 2015 Apr 02;4(5):e1026531. doi: 10.1080/2162402X.2015.1026531. eCollection 2015 May. PMID: 26155408; PMCID: PMC4485755.
Copy Download .nbib Format: NLM
Prognostic and theranostic impact of molecular subtypes and immune classifications in renal cell cancer (RCC) and colorectal cancer (CRC).

Oncoimmunology

Becht E, Giraldo NA, Beuselinck B, Job S, Marisa L, Vano Y, Oudard S, Zucman-Rossi J, Laurent-Puig P, Sautès-Fridman C, de Reyniès A, Fridman WH.
PMID: 26587318
Oncoimmunology. 2015 Aug 07;4(12):e1049804. doi: 10.1080/2162402X.2015.1049804. eCollection 2015 Dec.

Molecular and immune classifications powerfully predict cancer patient's survival and response to therapies. We herein describe the immune tumor microenvironment of molecular subgroups of colorectal and renal cell cancers, revealing a strong correlation between tumor subtypes and distinct immune...

Cite
Becht E, Giraldo NA, Beuselinck B, et al. Prognostic and theranostic impact of molecular subtypes and immune classifications in renal cell cancer (RCC) and colorectal cancer (CRC). Oncoimmunology. 2015;4(12):e1049804doi: 10.1080/2162402X.2015.1049804.
Becht, E., Giraldo, N. A., Beuselinck, B., Job, S., Marisa, L., Vano, Y., Oudard, S., Zucman-Rossi, J., Laurent-Puig, P., Sautès-Fridman, C., de Reyniès, A., & Fridman, W. H. (2015). Prognostic and theranostic impact of molecular subtypes and immune classifications in renal cell cancer (RCC) and colorectal cancer (CRC). Oncoimmunology, 4(12), e1049804. https://doi.org/10.1080/2162402X.2015.1049804
Becht, Etienne, et al. "Prognostic and theranostic impact of molecular subtypes and immune classifications in renal cell cancer (RCC) and colorectal cancer (CRC)." Oncoimmunology vol. 4,12 (2015): e1049804. doi: https://doi.org/10.1080/2162402X.2015.1049804
Becht E, Giraldo NA, Beuselinck B, Job S, Marisa L, Vano Y, Oudard S, Zucman-Rossi J, Laurent-Puig P, Sautès-Fridman C, de Reyniès A, Fridman WH. Prognostic and theranostic impact of molecular subtypes and immune classifications in renal cell cancer (RCC) and colorectal cancer (CRC). Oncoimmunology. 2015 Aug 07;4(12):e1049804. doi: 10.1080/2162402X.2015.1049804. eCollection 2015 Dec. PMID: 26587318; PMCID: PMC4635888.
Copy Download .nbib Format: NLM
Metastatic melanomas express inhibitory low affinity fc gamma receptor and escape humoral immunity.

Dermatology research and practice

Cohen-Solal JF, Cassard L, Fournier EM, Loncar SM, Fridman WH, Sautès-Fridman C.
PMID: 20672001
Dermatol Res Pract. 2010;2010:657406. doi: 10.1155/2010/657406. Epub 2010 Jun 28.

Our research, inspired by the pioneering works of Isaac Witz in the 1980s, established that 40% of human metastatic melanomas express ectopically inhibitory Fc gamma receptors (FcgammaRIIB), while they are detected on less than 5% of primary cutaneous melanoma...

Cite
Cohen-Solal JF, Cassard L, Fournier EM, et al. Metastatic melanomas express inhibitory low affinity fc gamma receptor and escape humoral immunity. Dermatol Res Pract. 2010;2010:657406doi: 10.1155/2010/657406.
Cohen-Solal, J. F., Cassard, L., Fournier, E. M., Loncar, S. M., Fridman, W. H., & Sautès-Fridman, C. (2010). Metastatic melanomas express inhibitory low affinity fc gamma receptor and escape humoral immunity. Dermatology research and practice, 2010657406. https://doi.org/10.1155/2010/657406
Cohen-Solal, Joel F G, et al. "Metastatic melanomas express inhibitory low affinity fc gamma receptor and escape humoral immunity." Dermatology research and practice vol. 2010 (2010): 657406. doi: https://doi.org/10.1155/2010/657406
Cohen-Solal JF, Cassard L, Fournier EM, Loncar SM, Fridman WH, Sautès-Fridman C. Metastatic melanomas express inhibitory low affinity fc gamma receptor and escape humoral immunity. Dermatol Res Pract. 2010;2010:657406. doi: 10.1155/2010/657406. Epub 2010 Jun 28. PMID: 20672001; PMCID: PMC2905727.
Copy Download .nbib Format: NLM
Trial watch: FDA-approved Toll-like receptor agonists for cancer therapy.

Oncoimmunology

Vacchelli E, Galluzzi L, Eggermont A, Fridman WH, Galon J, Sautès-Fridman C, Tartour E, Zitvogel L, Kroemer G.
PMID: 23162757
Oncoimmunology. 2012 Sep 01;1(6):894-907. doi: 10.4161/onci.20931.

Toll-like receptors (TLRs) have first been characterized for their capacity to detect conserved microbial components like lipopolysaccharide (LPS) and double-stranded RNA, resulting in the elicitation of potent (innate) immune responses against invading pathogens. More recently, TLRs have also been...

Cite
Vacchelli E, Galluzzi L, Eggermont A, et al. Trial watch: FDA-approved Toll-like receptor agonists for cancer therapy. Oncoimmunology. 2012;1(6):894-907doi: 10.4161/onci.20931.
Vacchelli, E., Galluzzi, L., Eggermont, A., Fridman, W. H., Galon, J., Sautès-Fridman, C., Tartour, E., Zitvogel, L., & Kroemer, G. (2012). Trial watch: FDA-approved Toll-like receptor agonists for cancer therapy. Oncoimmunology, 1(6), 894-907. https://doi.org/10.4161/onci.20931
Vacchelli, Erika, et al. "Trial watch: FDA-approved Toll-like receptor agonists for cancer therapy." Oncoimmunology vol. 1,6 (2012): 894-907. doi: https://doi.org/10.4161/onci.20931
Vacchelli E, Galluzzi L, Eggermont A, Fridman WH, Galon J, Sautès-Fridman C, Tartour E, Zitvogel L, Kroemer G. Trial watch: FDA-approved Toll-like receptor agonists for cancer therapy. Oncoimmunology. 2012 Sep 01;1(6):894-907. doi: 10.4161/onci.20931. PMID: 23162757; PMCID: PMC3489745.
Copy Download .nbib Format: NLM
Trial Watch: Experimental Toll-like receptor agonists for cancer therapy.

Oncoimmunology

Galluzzi L, Vacchelli E, Eggermont A, Fridman WH, Galon J, Sautès-Fridman C, Tartour E, Zitvogel L, Kroemer G.
PMID: 22934262
Oncoimmunology. 2012 Aug 01;1(5):699-716. doi: 10.4161/onci.20696.

Toll-like receptors (TLRs) are prototypic pattern recognition receptors (PRRs) best known for their ability to activate the innate immune system in response to conserved microbial components such as lipopolysaccharide and double-stranded RNA. Accumulating evidence indicates that the function of...

Cite
Galluzzi L, Vacchelli E, Eggermont A, et al. Trial Watch: Experimental Toll-like receptor agonists for cancer therapy. Oncoimmunology. 2012;1(5):699-716doi: 10.4161/onci.20696.
Galluzzi, L., Vacchelli, E., Eggermont, A., Fridman, W. H., Galon, J., Sautès-Fridman, C., Tartour, E., Zitvogel, L., & Kroemer, G. (2012). Trial Watch: Experimental Toll-like receptor agonists for cancer therapy. Oncoimmunology, 1(5), 699-716. https://doi.org/10.4161/onci.20696
Galluzzi, Lorenzo, et al. "Trial Watch: Experimental Toll-like receptor agonists for cancer therapy." Oncoimmunology vol. 1,5 (2012): 699-716. doi: https://doi.org/10.4161/onci.20696
Galluzzi L, Vacchelli E, Eggermont A, Fridman WH, Galon J, Sautès-Fridman C, Tartour E, Zitvogel L, Kroemer G. Trial Watch: Experimental Toll-like receptor agonists for cancer therapy. Oncoimmunology. 2012 Aug 01;1(5):699-716. doi: 10.4161/onci.20696. PMID: 22934262; PMCID: PMC3429574.
Copy Download .nbib Format: NLM
Complement C1s and C4d as Prognostic Biomarkers in Renal Cancer: Emergence of Noncanonical Functions of C1s.

Cancer immunology research

Daugan MV, Revel M, Russick J, Dragon-Durey MA, Gaboriaud C, Robe-Rybkine T, Poillerat V, Grunenwald A, Lacroix G, Bougouin A, Meylan M, Verkarre V, Oudard SM, Mejean A, Vano YA, Perkins G, Validire P, Cathelineau X, Sanchez-Salas R, Damotte D, Fremeaux-Bacchi V, Cremer I, Sautès-Fridman C, Fridman WH, Roumenina LT.
PMID: 34039653
Cancer Immunol Res. 2021 Aug;9(8):891-908. doi: 10.1158/2326-6066.CIR-20-0532. Epub 2021 May 26.

The complement system plays a complex role in cancer. In clear cell renal cell carcinoma (ccRCC), local production of complement proteins drives tumor progression, but the mechanisms by which they do this are poorly understood. We found that complement...

Cite
Daugan MV, Revel M, Russick J, et al. Complement C1s and C4d as Prognostic Biomarkers in Renal Cancer: Emergence of Noncanonical Functions of C1s. Cancer Immunol Res. 2021;9(8):891-908doi: 10.1158/2326-6066.CIR-20-0532.
Daugan, M. V., Revel, M., Russick, J., Dragon-Durey, M. A., Gaboriaud, C., Robe-Rybkine, T., Poillerat, V., Grunenwald, A., Lacroix, G., Bougouin, A., Meylan, M., Verkarre, V., Oudard, S. M., Mejean, A., Vano, Y. A., Perkins, G., Validire, P., Cathelineau, X., Sanchez-Salas, R., Damotte, D., Fremeaux-Bacchi, V., Cremer, I., Sautès-Fridman, C., Fridman, W. H., & Roumenina, L. T. (2021). Complement C1s and C4d as Prognostic Biomarkers in Renal Cancer: Emergence of Noncanonical Functions of C1s. Cancer immunology research, 9(8), 891-908. https://doi.org/10.1158/2326-6066.CIR-20-0532
Daugan, Marie V, et al. "Complement C1s and C4d as Prognostic Biomarkers in Renal Cancer: Emergence of Noncanonical Functions of C1s." Cancer immunology research vol. 9,8 (2021): 891-908. doi: https://doi.org/10.1158/2326-6066.CIR-20-0532
Daugan MV, Revel M, Russick J, Dragon-Durey MA, Gaboriaud C, Robe-Rybkine T, Poillerat V, Grunenwald A, Lacroix G, Bougouin A, Meylan M, Verkarre V, Oudard SM, Mejean A, Vano YA, Perkins G, Validire P, Cathelineau X, Sanchez-Salas R, Damotte D, Fremeaux-Bacchi V, Cremer I, Sautès-Fridman C, Fridman WH, Roumenina LT. Complement C1s and C4d as Prognostic Biomarkers in Renal Cancer: Emergence of Noncanonical Functions of C1s. Cancer Immunol Res. 2021 Aug;9(8):891-908. doi: 10.1158/2326-6066.CIR-20-0532. Epub 2021 May 26. PMID: 34039653.
Copy Download .nbib Format: NLM
Association of AXL and PD-L1 Expression with Clinical Outcomes in Patients with Advanced Renal Cell Carcinoma Treated with PD-1 Blockade.

Clinical cancer research : an official journal of the American Association for Cancer Research

Terry S, Dalban C, Rioux-Leclercq N, Adam J, Meylan M, Buart S, Bougoüin A, Lespagnol A, Dugay F, Moreno IC, Lacroix G, Lorens JB, Gausdal G, Fridman WH, Mami-Chouaib F, Chaput N, Beuselinck B, Chabaud S, Barros-Monteiro J, Vano Y, Escudier B, Sautès-Fridman C, Albiges L, Chouaib S.
PMID: 34407968
Clin Cancer Res. 2021 Dec 15;27(24):6749-6760. doi: 10.1158/1078-0432.CCR-21-0972. Epub 2021 Aug 18.

PURPOSE: A minority of patients currently respond to single-agent immune-checkpoint blockade (ICB), and strategies to increase response rates are urgently needed. AXL is a receptor tyrosine kinase commonly associated with drug resistance and poor prognosis in many cancer types,...

Cite
Terry S, Dalban C, Rioux-Leclercq N, et al. Association of AXL and PD-L1 Expression with Clinical Outcomes in Patients with Advanced Renal Cell Carcinoma Treated with PD-1 Blockade. Clin Cancer Res. 2021;27(24):6749-6760doi: 10.1158/1078-0432.CCR-21-0972.
Terry, S., Dalban, C., Rioux-Leclercq, N., Adam, J., Meylan, M., Buart, S., Bougoüin, A., Lespagnol, A., Dugay, F., Moreno, I. C., Lacroix, G., Lorens, J. B., Gausdal, G., Fridman, W. H., Mami-Chouaib, F., Chaput, N., Beuselinck, B., Chabaud, S., Barros-Monteiro, J., Vano, Y., Escudier, B., Sautès-Fridman, C., Albiges, L., & Chouaib, S. (2021). Association of AXL and PD-L1 Expression with Clinical Outcomes in Patients with Advanced Renal Cell Carcinoma Treated with PD-1 Blockade. Clinical cancer research : an official journal of the American Association for Cancer Research, 27(24), 6749-6760. https://doi.org/10.1158/1078-0432.CCR-21-0972
Terry, Stéphane, et al. "Association of AXL and PD-L1 Expression with Clinical Outcomes in Patients with Advanced Renal Cell Carcinoma Treated with PD-1 Blockade." Clinical cancer research : an official journal of the American Association for Cancer Research vol. 27,24 (2021): 6749-6760. doi: https://doi.org/10.1158/1078-0432.CCR-21-0972
Terry S, Dalban C, Rioux-Leclercq N, Adam J, Meylan M, Buart S, Bougoüin A, Lespagnol A, Dugay F, Moreno IC, Lacroix G, Lorens JB, Gausdal G, Fridman WH, Mami-Chouaib F, Chaput N, Beuselinck B, Chabaud S, Barros-Monteiro J, Vano Y, Escudier B, Sautès-Fridman C, Albiges L, Chouaib S. Association of AXL and PD-L1 Expression with Clinical Outcomes in Patients with Advanced Renal Cell Carcinoma Treated with PD-1 Blockade. Clin Cancer Res. 2021 Dec 15;27(24):6749-6760. doi: 10.1158/1078-0432.CCR-21-0972. Epub 2021 Aug 18. PMID: 34407968.
Copy Download .nbib Format: NLM
Trial watch: Oncolytic viruses for cancer therapy.

Oncoimmunology

Vacchelli E, Eggermont A, Sautès-Fridman C, Galon J, Zitvogel L, Kroemer G, Galluzzi L.
PMID: 23894720
Oncoimmunology. 2013 Jun 01;2(6):e24612. doi: 10.4161/onci.24612. Epub 2013 Apr 16.

Oncolytic virotherapy is emerging as a promising approach for the treatment of several neoplasms. The term "oncolytic viruses" is generally employed to indicate naturally occurring or genetically engineered attenuated viral particles that cause the demise of malignant cells while...

Cite
Vacchelli E, Eggermont A, Sautès-Fridman C, et al. Trial watch: Oncolytic viruses for cancer therapy. Oncoimmunology. 2013;2(6):e24612doi: 10.4161/onci.24612.
Vacchelli, E., Eggermont, A., Sautès-Fridman, C., Galon, J., Zitvogel, L., Kroemer, G., & Galluzzi, L. (2013). Trial watch: Oncolytic viruses for cancer therapy. Oncoimmunology, 2(6), e24612. https://doi.org/10.4161/onci.24612
Vacchelli, Erika, et al. "Trial watch: Oncolytic viruses for cancer therapy." Oncoimmunology vol. 2,6 (2013): e24612. doi: https://doi.org/10.4161/onci.24612
Vacchelli E, Eggermont A, Sautès-Fridman C, Galon J, Zitvogel L, Kroemer G, Galluzzi L. Trial watch: Oncolytic viruses for cancer therapy. Oncoimmunology. 2013 Jun 01;2(6):e24612. doi: 10.4161/onci.24612. Epub 2013 Apr 16. PMID: 23894720; PMCID: PMC3716755.
Copy Download .nbib Format: NLM
Trial Watch: Tumor-targeting monoclonal antibodies in cancer therapy.

Oncoimmunology

Vacchelli E, Aranda F, Eggermont A, Galon J, Sautès-Fridman C, Zitvogel L, Kroemer G, Galluzzi L.
PMID: 24605265
Oncoimmunology. 2014 Jan 01;3(1):e27048. doi: 10.4161/onci.27048.

In 1997, for the first time in history, a monoclonal antibody (mAb), i.e., the chimeric anti-CD20 molecule rituximab, was approved by the US Food and Drug Administration for use in cancer patients. Since then, the panel of mAbs that...

Cite
Vacchelli E, Aranda F, Eggermont A, et al. Trial Watch: Tumor-targeting monoclonal antibodies in cancer therapy. Oncoimmunology. 2014;3(1):e27048doi: 10.4161/onci.27048.
Vacchelli, E., Aranda, F., Eggermont, A., Galon, J., Sautès-Fridman, C., Zitvogel, L., Kroemer, G., & Galluzzi, L. (2014). Trial Watch: Tumor-targeting monoclonal antibodies in cancer therapy. Oncoimmunology, 3(1), e27048. https://doi.org/10.4161/onci.27048
Vacchelli, Erika, et al. "Trial Watch: Tumor-targeting monoclonal antibodies in cancer therapy." Oncoimmunology vol. 3,1 (2014): e27048. doi: https://doi.org/10.4161/onci.27048
Vacchelli E, Aranda F, Eggermont A, Galon J, Sautès-Fridman C, Zitvogel L, Kroemer G, Galluzzi L. Trial Watch: Tumor-targeting monoclonal antibodies in cancer therapy. Oncoimmunology. 2014 Jan 01;3(1):e27048. doi: 10.4161/onci.27048. PMID: 24605265; PMCID: PMC3937194.
Copy Download .nbib Format: NLM
Tertiary lymphoid structures in human lung cancers, a new driver of antitumor immune responses.

Oncoimmunology

Goc J, Fridman WH, Hammond SA, Sautès-Fridman C, Dieu-Nosjean MC.
PMID: 25083325
Oncoimmunology. 2014 May 29;3:e28976. doi: 10.4161/onci.28976. eCollection 2014.

T-cell infiltrates are robust prognostic biomarkers in the majority of human cancers. However, the mechanisms that shape a protective T-cell response remain unclear. Our recent study implicates tertiary lymphoid structures in the shaping of an efficient and beneficial immune...

Cite
Goc J, Fridman WH, Hammond SA, et al. Tertiary lymphoid structures in human lung cancers, a new driver of antitumor immune responses. Oncoimmunology. 2014;3:e28976doi: 10.4161/onci.28976.
Goc, J., Fridman, W. H., Hammond, S. A., Sautès-Fridman, C., & Dieu-Nosjean, M. C. (2014). Tertiary lymphoid structures in human lung cancers, a new driver of antitumor immune responses. Oncoimmunology, 3e28976. https://doi.org/10.4161/onci.28976
Goc, Jérémy, et al. "Tertiary lymphoid structures in human lung cancers, a new driver of antitumor immune responses." Oncoimmunology vol. 3 (2014): e28976. doi: https://doi.org/10.4161/onci.28976
Goc J, Fridman WH, Hammond SA, Sautès-Fridman C, Dieu-Nosjean MC. Tertiary lymphoid structures in human lung cancers, a new driver of antitumor immune responses. Oncoimmunology. 2014 May 29;3:e28976. doi: 10.4161/onci.28976. eCollection 2014. PMID: 25083325; PMCID: PMC4106161.
Copy Download .nbib Format: NLM
Trial Watch: Peptide-based anticancer vaccines.

Oncoimmunology

Pol J, Bloy N, Buqué A, Eggermont A, Cremer I, Sautès-Fridman C, Galon J, Tartour E, Zitvogel L, Kroemer G, Galluzzi L.
PMID: 26137405
Oncoimmunology. 2015 Jan 09;4(4):e974411. doi: 10.4161/2162402X.2014.974411. eCollection 2015 Apr.

Malignant cells express antigens that can be harnessed to elicit anticancer immune responses. One approach to achieve such goal consists in the administration of tumor-associated antigens (TAAs) or peptides thereof as recombinant proteins in the presence of adequate adjuvants....

Cite
Pol J, Bloy N, Buqué A, et al. Trial Watch: Peptide-based anticancer vaccines. Oncoimmunology. 2015;4(4):e974411doi: 10.4161/2162402X.2014.974411.
Pol, J., Bloy, N., Buqué, A., Eggermont, A., Cremer, I., Sautès-Fridman, C., Galon, J., Tartour, E., Zitvogel, L., Kroemer, G., & Galluzzi, L. (2015). Trial Watch: Peptide-based anticancer vaccines. Oncoimmunology, 4(4), e974411. https://doi.org/10.4161/2162402X.2014.974411
Pol, Jonathan, et al. "Trial Watch: Peptide-based anticancer vaccines." Oncoimmunology vol. 4,4 (2015): e974411. doi: https://doi.org/10.4161/2162402X.2014.974411
Pol J, Bloy N, Buqué A, Eggermont A, Cremer I, Sautès-Fridman C, Galon J, Tartour E, Zitvogel L, Kroemer G, Galluzzi L. Trial Watch: Peptide-based anticancer vaccines. Oncoimmunology. 2015 Jan 09;4(4):e974411. doi: 10.4161/2162402X.2014.974411. eCollection 2015 Apr. PMID: 26137405; PMCID: PMC4485775.
Copy Download .nbib Format: NLM
Complement C1s and C4d as Prognostic Biomarkers in Renal Cancer: Emergence of Noncanonical Functions of C1s.

Cancer immunology research

Daugan MV, Revel M, Russick J, Dragon-Durey MA, Gaboriaud C, Robe-Rybkine T, Poillerat V, Grunenwald A, Lacroix G, Bougouin A, Meylan M, Verkarre V, Oudard SM, Mejean A, Vano YA, Perkins G, Validire P, Cathelineau X, Sanchez-Salas R, Damotte D, Fremeaux-Bacchi V, Cremer I, Sautès-Fridman C, Fridman WH, Roumenina LT.
PMID: 34039653
Cancer Immunol Res. 2021 Aug;9(8):891-908. doi: 10.1158/2326-6066.CIR-20-0532. Epub 2021 May 26.

The complement system plays a complex role in cancer. In clear cell renal cell carcinoma (ccRCC), local production of complement proteins drives tumor progression, but the mechanisms by which they do this are poorly understood. We found that complement...

Cite
Daugan MV, Revel M, Russick J, et al. Complement C1s and C4d as Prognostic Biomarkers in Renal Cancer: Emergence of Noncanonical Functions of C1s. Cancer Immunol Res. 2021;9(8):891-908doi: 10.1158/2326-6066.CIR-20-0532.
Daugan, M. V., Revel, M., Russick, J., Dragon-Durey, M. A., Gaboriaud, C., Robe-Rybkine, T., Poillerat, V., Grunenwald, A., Lacroix, G., Bougouin, A., Meylan, M., Verkarre, V., Oudard, S. M., Mejean, A., Vano, Y. A., Perkins, G., Validire, P., Cathelineau, X., Sanchez-Salas, R., Damotte, D., Fremeaux-Bacchi, V., Cremer, I., Sautès-Fridman, C., Fridman, W. H., & Roumenina, L. T. (2021). Complement C1s and C4d as Prognostic Biomarkers in Renal Cancer: Emergence of Noncanonical Functions of C1s. Cancer immunology research, 9(8), 891-908. https://doi.org/10.1158/2326-6066.CIR-20-0532
Daugan, Marie V, et al. "Complement C1s and C4d as Prognostic Biomarkers in Renal Cancer: Emergence of Noncanonical Functions of C1s." Cancer immunology research vol. 9,8 (2021): 891-908. doi: https://doi.org/10.1158/2326-6066.CIR-20-0532
Daugan MV, Revel M, Russick J, Dragon-Durey MA, Gaboriaud C, Robe-Rybkine T, Poillerat V, Grunenwald A, Lacroix G, Bougouin A, Meylan M, Verkarre V, Oudard SM, Mejean A, Vano YA, Perkins G, Validire P, Cathelineau X, Sanchez-Salas R, Damotte D, Fremeaux-Bacchi V, Cremer I, Sautès-Fridman C, Fridman WH, Roumenina LT. Complement C1s and C4d as Prognostic Biomarkers in Renal Cancer: Emergence of Noncanonical Functions of C1s. Cancer Immunol Res. 2021 Aug;9(8):891-908. doi: 10.1158/2326-6066.CIR-20-0532. Epub 2021 May 26. PMID: 34039653.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 47 entries